Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amuvatinib + paclitaxel + carboplatin
- Development stage
- Phase 1
- Lead developer
- Supergene
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Amuvatinib (MP-470) is an orally bioavailable, synthetic small molecule that acts as a multi-targeted tyrosine kinase inhibitor. It inhibits mutant and wild-type forms of c-Kit, PDGFRα, Flt3, c-Met, RET proto-oncogene, AXL receptor tyrosine kinase, and the DNA repair protein Rad51 recombinase. By blocking these kinases and interfering with DNA repair mechanisms in cancer cells, amuvatinib exhibits antineoplastic activity and can potentiate the effects of DNA-damaging agents such as chemotherapy. Amuvatinib has been studied in combination with standard chemotherapeutic agents like paclitaxel (a microtubule stabilizer) and carboplatin (a platinum-based DNA crosslinker), particularly for solid tumors including small cell lung carcinoma. The combination aims to enhance tumor cell death by targeting multiple pathways involved in tumor growth and resistance[1][2][4][5][8].
- Other names
- amuvatinib
02
Targets
AXL (AXL receptor tyrosine kinase)DNAFLT3 (Fms related receptor tyrosine kinase 3)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)RAD51 (RAD51 Recombinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on amuvatinib + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amuvatinib + paclitaxel + carboplatin.